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Abstract
Background: Consensus on the optimum choice of cardioplegia remains elusive. One
possibility that has been suggested to have beneficial properties is microplegia, a
cardioplegia of reduced crystalloid volume. The aim of this meta‐analysis is to
comprehensively investigate microplegia against a range of clinical outcomes.
Methods: To identify potential studies, systematic searches were carried out in four
databases (eg, Pubmed, EMBASE). The search strategy included the key concepts of
“microplegia” OR “mini‐cardioplegia” OR “miniplegia” AND “cardiac surgery.” This
was followed by a meta‐analysis investigating: mortality, crystalloid volume; cardi-
opulmonary bypass time; cross‐clamp time; intra‐aortic balloon pump use; sponta-
neous heartbeat recovery; inotropic support; low cardiac output syndrome;
myocardial infarction; acute renal failure; atrial fibrillation, reoperation for bleeding;
creatine kinase myocardial band (CK‐MB); intensive care unit (ICU) time and hos-
pital stay.
Results: Eleven studies comprising 5798 participants were analyzed. Microplegia
used a lower volume of crystalloids and led to a higher spontaneous return of
heartbeat, odds ratio (OR) 4.271 (95% confidence intervals [CIs]: 1.935, 9.423;
I2 = 76.57%; P < .001) and a lower requirement for inotropic support, OR: 0.665
(95% CI: 0.47, 0.941; I2 = 3.53%; P = .021). Microplegia was also associated with a
lower CK‐MB release, mean difference (MD) −6.448 ng/mL (95% CI: −9.386, −3.511;
I2 = 0%; P < .001) and a shorter ICU stay, MD: −0.411 days (95% CI: −0.812, −0.009;
I2 = 17.65%; P = .045). All other comparisons were nonsignificant.
Conclusions: Microplegia has similar effects to other types of cardioplegia and is
beneficial with regard to spontaneous return of heartbeat, inotropic support, ICU
stay, and CK‐MB release.
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1 | INTRODUCTION
Cardiopulmonary bypass (CPB) provides physiological support
through an extracorporeal circuit, circumventing the heart, which is
afforded a bloodless field by aortic cross‐clamp. Uncontrolled myo-
cardial oxygen consumption in these conditions and at the time of
unclamping could predispose the myocardium to injury. By perfusing
the heart with a cardioplegic solution to induce and maintain elec-
tromechanical arrest, Sarkar et al1 acknowledge that cardioprotec-
tive strategies arise from managed myocardial oxygen consumption.
Cardioplegia modalities were based on three main principles:
chemical arrest, hypothermia, and the addition of extra antiischaemic
chemicals.2 Over the years, there have been many variations of
cardioplegia in terms of the ingredients of crystalloid cardioplegia,
the temperature and the direction of delivery.3 One of the most
enduring debates is whether to use blood or crystalloid cardioplegia.
The argument for blood cardioplegia centres around its buffering
ability, normal oncotic pressure, free radical scavenging potential,
and improved oxygen delivery.3,4 The two meta‐analyses that have
been carried out, suggest a lower risk of perioperative myocardial
infarction (MI),4 a lower incidence of low cardiac output syndrome
(LCOS), and lower creatine kinase myocardial band (CK‐MB) release
with blood cardioplegia.5
Standard formulation of blood cardioplegia tends to be either
four or eight parts blood to one part crystalloid.6 Pure blood cardi-
oplegia of reduced volume and delivered intermittently,7 otherwise
known as microplegia is an alternative to this. The main advantages
reported here include less haemodilution, reduced myocardial oe-
dema, and rapid recovery of ventricular function.6‐8 In addition, the
intermittent dosing in microplegia could play a vital role in managing
harmful inflammatory responses to global ischemia and regional
reperfusion, whereas diluted cardioplegia could have less control in
its single‐dose modality.1
Early clinical trials reported the use of less vasopressors8 and
better postoperative left ventricular function9 with microplegia.
More recent trials have consistently shown a higher establishment of
spontaneous heartbeat return using microplegia when compared to
standard diluted blood cardioplegia.10,11 One drawback to these
studies was low statistical power suggesting the need for a larger
analysis/meta‐analysis to investigate for true differences. There has
been one meta‐analysis conducted, which investigated studies up to
May 2013. This old meta‐analysis contained a limited number of
studies and outcomes.12 The aim of the current comprehensive meta‐
analysis (CMA) was to investigate the effect of microplegia in a range
of clinical and biochemical outcomes to other types of cardioplegia
for myocardial protection for patients undergoing cardiac surgery.
2 | METHODS
This systematic review and meta‐analysis were performed in ac-
cordance with the PRISMA guidelines (see Supporting Information
Files).
2.1 | Search strategy
To identify potential studies systematic searches were carried out
using: EMBASE, PubMed, Web of Science, and the Cochrane Central
Registry of Controlled Trials. The search was supplemented by
scanning the reference lists of eligible studies. The search strategy
included the key concepts of “microplegia”OR “mini‐cardioplegia”OR
“miniplegia” AND “cardiac surgery” (see Supporting Information
Files). All identified papers were assessed independently by two re-
viewers. A third reviewer was consulted to resolve disputes. Searches
of published papers were conducted up until 1st February 2020.
Data were extracted using predesigned extraction tables.
2.2 | Types of trials to be included and excluded
Included trials were those that directly compared the use of micro-
plegia versus any other type of cardioplegia in open‐heart surgery.
There were no language restrictions. Animal studies and review pa-
pers were excluded. Studies that did not have any of the desired
outcome measures were excluded. Incomplete data, or data from an
already included study, were excluded. Other treatment modalities
and interventions for coronary artery disease such as percutaneous
coronary intervention and valvular disease such as transcatheter
aortic valve intervention were excluded.
2.3 | Participants/population
This meta‐analysis analysed randomized controlled trials (RCTs) and
case‐control trials of both male and female adult (≥18 years) patients
with coronary artery disease or valvular disease who were under-
going cardiac surgery using either microplegia or other types of
cardioplegia.
2.4 | Intervention(s), exposure(s)
This meta‐analysis considered all RCTs and case‐control trials where
microplegia or another type of cardioplegia were used in either coronary
artery bypass graft (CABG) or in patients treated for valvular disease.
More specifically, all RCTs and retrospective trials where the interven-
tion of carrying out cardiac surgery using microplegia was performed.
2.5 | Search results
Our initial search found 46 articles of which 25 duplicate studies
were excluded. A further four studies were excluded as they were
investigating paediatric cases; one study was excluded as it had
no reported outcomes; one paper was excluded because it was a
review; one paper was excluded because it contained duplicate
data; and, three studies were excluded because they had no
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comparator group (Figure 1). Eleven studies were included in our
analysis.6,8‐11,13‐18
2.6 | Outcomes
The primary outcomes analysed were: mortality, volume of crystal-
loids used, CPB time, aortic cross‐clamp time, intra‐aortic balloon
pump (IABP) use, spontaneous heartbeat recovery, inotropic support,
LCOS, MI, acute renal failure, atrial fibrillation (AF), reoperation for
bleeding, CK‐MB, intensive care unit (ICU) time and hospital stay.
2.7 | Risk of bias (quality) assessment
Risk of bias was assessed using a modified Jadad scale for
randomized controlled trials19 and the Newcastle‐Ottawa Scale
(http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp) for
case‐control studies. Publication bias was investigated using funnel
plots.20
2.8 | Data synthesis
In the following analyses, the non‐microplegia group is referred to
as diluted cardioplegia. Odds ratios (OR) were calculated for
dichotomous data. Continuous data were compared using mean
differences (MDs). Where necessary medians and interquartile
ranges were converted into means and standard deviations using
the method of Hozo et al.21 Subgroup analyses were carried out
to investigate differences in the diluted cardioplegia arm. All
analyses were conducted using CMA version 3. Heterogeneity
was quantified using the Cochrane Q test22 and all comparisons
were made using random effects. We used a 5% level of
significance and 95% confidence intervals (CIs); figures were
produced using CMA. Funnel plots were used to analyse pub-
lication bias. Ideally, the results of all trials carried out to in-
vestigate the effects of microplegia in comparison to other types
of cardioplegia would be published. Unfortunately, in reality, not
all trials are published, potentialy leading to selective reporting or
publication bias. This can be detected in a funnel plot that is
asymmetrical.
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3 | RESULTS
The eleven studies6,8‐11,13‐18 included in the analysis had an aggregate
of 5684 participants, 2681 of whom were microplegia patients versus
3003 who received other types of cardioplegia. The characteristics of
the included studies are summarized in Table 1. The excluded RCT's and
reasons for exclusion are listed in Table S1. The results are summarized
with mortality leading, followed by intra‐operative and then post-
operative variables. A summary of the results is presented in Table 2.
3.1 | Mortality
Five studies involving 5358 patients reported the incidence of mortality.
The OR for the comparison was 1.36 (95% CI: 0.95‐1.93; I² = 0%;
P = .090) (Figure 2). There was no significant difference in the odds of
mortality between the two groups. The funnel plot was symmetrical.
3.2 | Volume of crystalloids
The majority of trials reported a difference in the volume of crystalloids
in the microplegia compared to the diluted cardioplegia. The exceptions
were Koechlin et al18 and Onorati16 where volumes were not reported.
In the two trials by Lopez Menendez et al,13,14 the volume of crystal-
loids in the microplegia was not given but reported to be “minimal.” In
Menasche et al8 the volume of diluted cardioplegia was 1000mL
compared to 58 ± 14mL (P = .0001), whilst in Albacker et al17 the
volume of crystalloids in the diluted cardioplegia was 740 CC (95% CI:
690‐794) compared to 65 CC (95% CI: 62‐67) (P < .01). Four trials in-
volving 196 patients reported the volume of crystalloids in mL used in
the cardioplegia. The MD between the groups was −396.77mL (95% CI:
−422.93, −370.62; I2 = 94.07%; P < .001) (Figure S1). The volume of
crystalloids used in the microplegia group was significantly lower than
the diluted cardioplegia group. The funnel plot was symmetrical.
3.3 | CPB time
Nine studies involving 5403 patients reported the length of time on CPB.
The MD between the two groups was −0.87minutes (95% CI: −4.51 to
2.78; I2 = 92%; P= .640) (Figure S2). There was no significant difference in
CPB time between patients receiving microplegia and patients receiving
diluted cardioplegia. The funnel plot was asymmetrical.
3.4 | Aortic cross‐clamp time
Nine studies involving 4983 patients reported the time of aortic
cross‐clamping. The MD between the groups was −1.07 minutes
(95% CI: −4.54 to 2.39; I2 = 90%; P = .544) (Figure S3). There was no
significant difference in aortic cross‐clamp time between the two
groups. The funnel plot was asymmetrical.
3.5 | Intra‐aortic balloon pump
Four studies involving 4939 patients reported the requirement for
IABP. The OR for the comparison was 0.81 (95% CI: 0.50‐1.31;
I2 = 0%; P = .386) (Figure S4). The two groups showed no significant
difference in their requirement for IABP. The funnel plot was
symmetrical.
3.6 | Spontaneous heartbeat recovery
Six studies involving 1122 patients reported the incidence of spon-
taneous heartbeat recovery after aortic unclamping. The OR was
4.27 (95% CI: 1.94‐9.42; I2 = 77%; P < .001) (Figure 3). There was a
significantly higher incidence of spontaneous heartbeat recovery in
the microplegia group than in the diluted cardioplegia group. The
funnel plot was asymmetrical.
3.7 | Inotropic support
Five studies involving 1233 patients reported the need for post-
operative inotropic support. The OR was 0.67 (95% CI: 0.47‐0.94;
I2 = 4%; P = .021) (Figure S5). There was a significantly lower re-
quirement for inotropic support in the microplegia group compared
to the diluted cardioplegia group. The funnel plot was symmetrical.
3.8 | Low cardiac output syndrome
Four studies involving 4149 patients reported the incidence of
LCOS. The OR for the comparison was 0.67 (95% CI: 0.37‐1.20;
I2 = 27%; P = .175) (Figure S6). The incidence of LCOS was not
statistically significant between the two groups. The funnel plot
was symmetrical.
3.9 | Myocardial infarction
Three studies involving 4230 patients reported the incidence of MI
as a postoperative complication. The OR for the comparison was 0.86
(95% CI: 0.26‐2.92; I2 = 0%; P = .811) (Figure S7). There was no sig-
nificant difference in MI incidence between the two groups. The
funnel plot was symmetrical.
3.10 | Acute renal failure
Five studies involving 5358 patients reported the incidence of acute
renal failure. The OR for the comparison was 0.96 (95% CI: 0.56‐
1.65; I2 = 43%; P = .876) (Figure S8). There was no significant differ-
ence in the odds of postoperative acute renal failure between the
two groups. The funnel plot was symmetrical.
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3.11 | Atrial fibrillation
Three studies involving 300 patients reported the incidence of
postoperative AF. The OR for the comparison was 0.88 (95% CI:
0.34‐2.26; I2 = 43%; P = .784) (Figure S9). There was no significant
difference in the odds of triggering AF between the two groups. The
funnel plot was symmetrical.
3.12 | Reoperation for bleeding
Three studies involving 1103 patients reported the incidence of re-
operation for bleeding. The OR for the comparison was 1.15 (95% CI:
0.51‐2.58; I2 = 21%; P = .741) (Figure S10). The two groups showed
no significant difference in the need to reoperate for bleeding. The
funnel plot was symmetrical.
TABLE 2 Summary of results
Parameter Effect measure LL UL P I2 (%)
Mortality 1.36 OR 0.95 1.93 .090 0
Volume of crystalloids −396.77mL MD −422.93 −370.62 <.001 94.07
CPB time −0.87min MD −4.51 2.78 .640 92
Aortic cross‐clamp time −1.07min MD −4.54 2.39 .544 90
Intra‐aortic balloon pump use 0.81 0.5 1.31 .386 0
Spontaneous heartbeat recovery 4.27 OR 1.94 9.42 <.001 77
Inotropic support 0.67 OR 0.47 0.94 .021 4
Low cardiac output syndrome 0.67 OR 0.37 1.2 .175 27
Myocardial infarction 0.86 OR 0.26 2.92 .811 0
Acute renal failure 0.96 OR 0.56 1.65 .8766 43
Atrial fibrillation 0.88 OR 0.34 2.26 .784 43
Reoperation for bleeding 1.15 OR 0.51 2.58 .741 21
CK‐MB release −6.45 ng/mL MD −9.39 −3.51 <.001 0
ICU time −0.41 d MD −0.81 −0.01 .045 18
Hospital stay −1.73 d MD −1.73 0.17 .109 57
Abbreviations: CK‐MB, creatine kinase myocardial band; CPB, cardiopulmonary bypass; ICU, intensive care unit; LL, lower 95% confidence interval; MD,
mean difference; OR, odds ratio; UL, upper 95% confidence interval.
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Albacker 2009 1.957 0.969 3.954 1.872 0.061
Algarni 2013 1.000 0.566 1.767 0.000 1.000
Koechlin 2019 1.567 0.809 3.037 1.330 0.183
Lopez-Menendez 2017 1.300 0.318 5.314 0.365 0.715
Lopez-Menendez 2018 0.543 0.026 11.492 -0.392 0.695
1.358 0.954 1.934 1.698 0.090
0.01 0.1 1 10 100
Favours MP Favours CP
Mortality
F IGURE 2 Mortality. On the left is a table displaying the odds ratio, lower limit, upper limit, Z value, and P value for each of the pooled
studies with the final line presenting the overall statistics. On the right is a forest plot, which displays the odds ratio (squares) and 95%
confidence intervals (whiskers) for each of the individual studies. Also shown is the overall odds ratio (diamond) where the width of the diamond
represents the 95% confidence intervals. CP, diluted cardioplegia; MP, microplegia
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3.13 | Release of CK‐MB
Five studies involving 504 patients reported the postoperative CK‐
MB plasma levels. The MD between the groups was −6.45 ng/mL
(95% CI: −9.39 to −3.51; I2 = 0%; P < .001) (Figure 4). The post-
operative concentration of CK‐MB in the microplegia patients was
significantly lower than in the diluted cardioplegia patients. The
funnel plot was symmetrical.
3.14 | Intensive care unit time
Four studies involving 411 patients reported the length of stay in the
ICU. The MD between the groups was −0.41 days (95% CI: −0.81 to
−0.01; I2 = 18%; P = .045) (Figure S11). Patients receiving microplegia
spent significantly less time in ICU than their diluted cardioplegia
counterparts. The funnel plot was asymmetrical.
3.15 | Hospital stay
Four studies involving 4310 patients reported the postoperative
length of stay in hospital. The MD between the groups was −0.78
days (95% CI: −1.73 to 0.17; I2 = 57%; P = .109) (Figure S12). There
was a trend toward the microplegia patients having less hospital stay
time, however, this did not reach statistical significance. The funnel
plot was asymmetrical.
3.16 | Subgroup analyses
A subset analysis was carried out examining all parameters in studies
under 10 years old. These results are presented in Table S2. It was
found that spontaneous return of heartbeat and LCOS were sig-
nificantly in favour of the microplegia group with all other compar-
isons nonsignificant.
Subgroup analyses were also performed for RCTs. These re-
sults are shown in Table S3. The results for CK‐MB, CPB time,
aortic cross‐clamp time, ICU time, inotropic support, and sponta-
neous return of heartbeat were all significantly in favour of the
microplegia group.
Further subgroup analyses were carried out with the results
presented in Table S4. These results largely followed the main data.
3.17 | Study quality
Two study quality tests were utilized: The Jadad Scale for RCTs and
the Newcastle‐Ottawa Scale for case‐controlled trials. The former
revealed a median score of 4 (Table S5). The Newcastle‐Ottawa Scale
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit Z-Value p-Value
Hayashi 2004 5.333 1.839 15.471 3.081 0.002
Hayashi 2006 9.750 1.592 59.695 2.463 0.014
Lopez-Menendez 2017 2.235 1.458 3.429 3.687 0.000
Lopez-Menendez 2018 7.881 4.186 14.836 6.396 0.000
Menasche 1993 0.219 0.023 2.114 -1.313 0.189
Onorati 2012 9.081 3.287 25.085 4.256 0.000
4.271 1.935 9.423 3.595 0.000
0.01 0.1 1 10 100
Favours MP Favours CP
Spontaneous Heart Beat Recovery F IGURE 3 Spontaneous return of heartbeat.
All details as Figure 1
Study name Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit Z-Value p-Value
El-Hamamsy 2004 12.700 -30.436 55.836 0.577 0.564
Hayashi 2004 -6.300 -11.145 -1.455 -2.549 0.011
Hayashi 2006 -7.100 -12.699 -1.501 -2.485 0.013
Hayashida 1998 -2.000 -11.885 7.885 -0.397 0.692
Koechlin 2019 -7.800 -13.517 -2.083 -2.674 0.007
-6.448 -9.386 -3.511 -4.302 0.000
-25.00 -12.50 0.00 12.50 25.00
Favours MP Favours CP
CKMB (ng/ml)
F IGURE 4 Creatine kinase myocardial band
release. Details similar to Figure 1 except the
statistics presented are mean differences
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reported largely good results with a median score of 8 out of 9
(Table S6).
4 | CONCLUSIONS
This CMA included 11 studies and compared the potential cardio-
protective capabilities of microplegia and diluted cardioplegia. We
found that microplegia used a lower crystalloid volume and was
beneficial with respect to spontaneous heartbeat recovery, inotropic
support, CK‐MB release, and ICU stay time. All of the other com-
parisons including mortality were not statistically significant. This
suggests that microplegia has similar effects compared to diluted
cardioplegia and may have some benefits.
The observation of spontaneous heartbeat recovery at aortic un-
clamping was statistically different between all of the microplegia and
diluted cardioplegic groups, excepting in one individual study.8 This was
also true in most of the subgroup analyses, with the notable exceptions of
aortic valve surgery, retrograde delivery, and warm delivery. Sponta-
neous return of heartbeat is proposed as an indicator of good myocardial
protection.13 Furthermore, it has been suggested by Onorati et al16 that
better myocardial protection using microplegia could be responsible for
their improved postoperative measurements in diastolic function.
CK‐MB is a highly specific and sensitive marker of myocardial
cell wall injury. Concentrations of this biomarker were significantly
increased in the diluted cardioplegia patients in all included individual
studies9‐11,15,18; in every subgroup analysis and in the meta‐analysis
overall. This could point to more optimal perioperative protection in
the microplegia patients but whether this translates to more positive
clinical outcome needs to be cross‐examined with other results. For
example, CK‐MB's diagnostic accuracy of over 90% sensitivity in
MI23 did not appear to correlate to MI incidence as there was no
difference between microplegia and diluted cardioplegia in the three
studies which were included in this meta‐analysis.6,15,18 It should be
noted, however, that the incidence of MI can be based on other
parameters such as ECG changes. Two papers did not state the
method used to identify MI,6,18 and the other used a variety of
diagnostic measures.
Systemic inflammation causing generalized vasodilation is a
common response in CPB. Furthermore, vasopressor agents used to
combat this may have a negative impact on native and graft coronary
flow24 so a demonstrable benefit of using microplegia in improving
graft patency and postoperative myocardial perfusion could be evi-
dent in the significantly decreased incidence of inotropic support in
this meta‐analysis. However, as shown by the subgroup analysis this
may be limited to CABG surgery and more applicable to the blood
cardioplegia group.
No differences were found in mortality incidence, No sig-
nificant differences were found in mortality incidence, although the
odds leant toward the diluted cardioplegia group. The main con-
tributing trial of mortality as a key outcome was Albacker et al.17 In
this trial, a significant crude mortality figure became insignificant
when preoperative and operative differences were accounted for.
The consensus that mortality incidence is not dissimilar in whole
blood cardioplegia and diluted cardioplegia is concluded in a
meta‐analysis by Zeng et al4 stating a clearer clinical correlation to
reduced myocardial injury by decreased release of enzymatic
markers than to mortality incidence.
ICU time was significantly reduced in microplegia patients. In-
dependent predictors of the length of time in ICU are multifactorial
but if we focus on the role of cardioplegia in protecting the myo-
cardium from inflammatory response during ischemia and reperfu-
sion, any reduction in myocardial oedema could, according to Onorati
et al16 improve LV functioning. This would in turn shorten the time
taken for the patient to reach haemodynamic stability suitable for
discharge from the ICU. A study on factors influencing prolonged ICU
stay in heart surgery found a significant association between length
of ICU stay and low LVEF less than 40%.25 A shortened stay in ICU is
also beneficial with respect to the mobilization of the patient redu-
cing the risk of development of ICU‐acquired weaknesses reported in
50% of patients discharged from the ICU and associated with in-
creased 90‐day mortality incidence.26 In addition to the significantly
shorter ICU stay, the hospital stay time was approximately three‐
quarters of a day shorter. These shortened stays could indicate a
significant financial saving.
4.1 | Limitations
Unfortunately, there is no consensus surrounding the choice of car-
dioplegia. This, therefore, created difficulty in finding a consistent
control arm for this study. To overcome this subgroup, analyses were
carried out for the significant results. This showed that some of mi-
croplegia's benefits were constrained under certain conditions. It was
noticeable though that no matter how the data were segregated,
there was always a lower CK‐MB release in the microplegia group.
In the majority of the significant analyses, the funnel plot was
symmetrical. The exception was spontaneous heartbeat recovery
suggesting the possible existence of some publication bias in this
finding.
Prospectively randomizing patients to either treatment techni-
que was performed in six of the studies.8‐11,15,16 As the sample sizes
in these studies were generally smaller, this meant that only 4.7% of
the 5798 participants were randomized.
4.2 | Conclusions
A clear consensus on the optimal cardioplegic solution has been
challenged by extensive variation in the composition, volume,
temperature, and delivery technique of cardioplegia across surgi-
cal practices. Microplegia is one of several different alternatives
mooted. This meta‐analysis shows that microplegia is similar to
other cardioplegia choices and may offer some advantages in
terms of early return to spontaneous heartbeat, less requirement
for inotropic support, shorter ICU stay, and lower CK‐MB release.
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